Overview

Once Daily Given Alfuzosin in the Treatment of BPH

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
Collection of the data on the safety and efficacy of the once daily administration of the alfuzosin preparation /Alfetim Uno® l0 mg/ at patients with lower urinary tract symptoms/complaints rendering possible the presence of benign prostatic hyperplasia, in the course of everyday practice
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Alfuzosin